METTL16 upregulation is associated with a poorer outcome in HCC patients and promotes malignant progression by promoting lncRNA RAB11B-AS1 degradation in an m6A-dependent manner [29]. The gene discussed is RAB11B; the disease is hepatocellular carcinoma.